Progress, Potential, and Possibilities Podcast / Show From Lab to Clinic: The Science Behind Exosome Therapy for Paralysis | Dr. Lior Shaltiel - Chief Executive Officer, NurExone Biologic
What if paralysis wasn’t permanent—but just a biological system we haven’t figured out how to reboot?
Dr. Lior Shaltiel, Ph.D. is Chief Executive Officer of NurExone Biologic ( https://nurexone.com/ ), a biotech company pioneering a novel exosome-based platform aimed at repairing the central nervous system.
Dr. Shaltiel brings a rare combination of deep scientific training and cross-border biotech leadership. He earned his Ph.D. in molecular pharmacology from Ludwig Maximilian University of Munich, where his research focused on ion channels and retinal biology - early work that connects directly to today’s frontier in neuroregeneration.
Before stepping into the CEO role, Dr. Shaltiel led R&D programs in advanced drug delivery systems, including liposome-based therapeutics, and worked in global biotech investment and partnerships. He’s also the founder of the BioMed MBA program at Hebrew University of Jerusalem, helping train the next generation of biotech leaders.
At NurExone, Dr. Shaltiel is advancing the company’s ExoTherapy platform - leveraging extracellular vesicles to deliver targeted genetic payloads. Their lead program, ExoPTEN, is an intranasal exosome therapy designed to silence the PTEN gene and promote neuronal regeneration after spinal cord injury - an area where, to date, there are no approved treatments that restore lost function.
#biotech #neuroscience #spinalcordinjury #regenerativemedicine #exosomes #stemcells #futureofmedicine #geneediting #biotechinnovation #medicalbreakthrough #neuroregeneration #sciencepodcast #healthtech #longevity #drugdiscovery #PTEN #RNAi #nextgenmedicine #biophysics #medtech